Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.6K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.6K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.6K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.6K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

955
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
955
Self-Efficacy01:29

Self-Efficacy

237
Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
237
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

6.6K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.6K
The Placebo Effect01:54

The Placebo Effect

6.9K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fruquintinib in combination with tislelizumab versus trifluridine/tipiracil and bevacizumab in third-line and beyond MSS mCRC without active liver metastases-the IKF-080/AIO-QUINTIS trial.

ESMO gastrointestinal oncology·2026
Same author

Virtual reality support during systemic cancer therapy to improve anxiety/depressive symptoms and reduce toxicity in patients with gastrointestinal cancers-OncoVR.

ESMO gastrointestinal oncology·2026
Same author

TROPHIT1-a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients.

ESMO gastrointestinal oncology·2026
Same author

Preoperative immunotherapy with atezolizumab and tiragolumab in patients with colorectal liver metastases-the PURPLE trial.

ESMO gastrointestinal oncology·2026
Same author

Human <i>in vivo</i> assessment of ketamine binding of the serotonin transporter-follow up at a higher dose.

Frontiers in neuroscience·2025
Same author

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2.

ESMO open·2025
Same journal

Evaluation of Oculomotor Function Following Sleep Improvement With Lemborexant in Older Adults With Insomnia.

Human psychopharmacology·2026
Same journal

Relationship Between Clozapine Levels and Adverse Effects Evaluated by the GASS-C in Treatment-Resistant Schizophrenia.

Human psychopharmacology·2026
Same journal

ADHD, Psychotropic Medication and Pregnancy: The Influence of Maternal ADHD on Child Development-A Retrospective Cohort Study.

Human psychopharmacology·2026
Same journal

Long-Term Trends in Prescribing of Etizolam for Hypnotic Use in a Japanese University Hospital.

Human psychopharmacology·2026
Same journal

Verbal and Visuospatial Working Memory Performance During the CO<sub>2</sub> Challenge Model of Anxiety.

Human psychopharmacology·2026
Same journal

Serum Galectin-1 and Galectin-3 Levels and Their Relationship With Executive Functions and Memory in Patients With Major Depressive Disorder.

Human psychopharmacology·2026
See all related articles

Related Experiment Video

Updated: Feb 12, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

3.2K

Do SSRIs differ in their antidepressant efficacy.

S Kasper1, A Heiden1

  • 1Department of General Psychiatry, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

Human Psychopharmacology
|March 24, 2018
PubMed
Summary
This summary is machine-generated.

Selective serotonin reuptuptake inhibitors (SSRIs) are as effective as tricyclic antidepressants (TCAs), with some showing better results for severe depression. Direct comparisons between SSRIs are limited but suggest equal efficacy, though side effects may influence usage patterns.

Keywords:
depressionefficacyselective serotonin reuptake inhibitors

More Related Videos

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.1K
Visualizing Efficacy of Pesticides Against Disease Vector Mosquitoes in the Field
10:49

Visualizing Efficacy of Pesticides Against Disease Vector Mosquitoes in the Field

Published on: March 16, 2019

9.1K

Related Experiment Videos

Last Updated: Feb 12, 2026

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug
07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

3.2K
Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
06:26

Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis

Published on: July 28, 2023

3.1K
Visualizing Efficacy of Pesticides Against Disease Vector Mosquitoes in the Field
10:49

Visualizing Efficacy of Pesticides Against Disease Vector Mosquitoes in the Field

Published on: March 16, 2019

9.1K

Area of Science:

  • Pharmacology
  • Psychiatry
  • Clinical Therapeutics

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are primary treatments for depression.
  • SSRIs demonstrate comparable efficacy to TCAs, with some evidence of superior outcomes in specific patient subgroups.

Purpose of the Study:

  • To review the comparative efficacy of SSRIs versus TCAs.
  • To highlight the lack of direct comparative data among different SSRIs.
  • To explore how pharmacokinetic and pharmacodynamic differences influence SSRI selection and usage.

Main Methods:

  • Literature review of existing studies comparing SSRIs and TCAs.
  • Analysis of available direct comparative data between different SSRIs.
  • Examination of pharmacodynamic and pharmacokinetic profiles of SSRIs.

Main Results:

  • SSRIs show at least equivalent efficacy to TCAs.
  • SSRIs may offer superior efficacy in patients with severe depression, suicidal ideation, or comorbid anxiety.
  • Limited direct comparative studies suggest overall equal efficacy among different SSRIs.
  • Pharmacokinetic and pharmacodynamic variations among SSRIs can lead to distinct side-effect profiles.

Conclusions:

  • SSRIs represent an effective treatment option for depression, comparable to TCAs.
  • Individual SSRI characteristics, particularly side effects, are crucial factors in clinical decision-making and patient adherence.
  • Further direct comparative studies on SSRIs are warranted to refine treatment selection.